Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants

With the increasing use of new regulatory tools, like the Food and Drug Administration’s breakthrough designation, there are increasing challenges for European health technology assessors (HTAs) to make an accurate assessment of the long-term value and performance of chimeric antigen receptor T-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulthess, Duane, Gassull, Daniel, Makady, Amr, Ludlow, Anna, Rothman, Brian, Have, Pieter ten, Wu, Yiyang, Ekstrom, Leeland, Minnema, Monique, Jagasia, Madan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
EBM analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165150/
https://www.ncbi.nlm.nih.gov/pubmed/31315904
http://dx.doi.org/10.1136/bmjebm-2019-111226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165150/
https://www.ncbi.nlm.nih.gov/pubmed/31315904
http://dx.doi.org/10.1136/bmjebm-2019-111226

Ejemplares similares